Clinical trials located in

Frimley

Frimley city is located in United Kingdom. Currently, 7 clinical trials are being conducted in this city.

Frimley, located in Surrey, England, is a small town with a rich history. Notably, it houses the Frimley Park Hospital, a major NHS hospital with a renowned maternity unit. The town is also home to the Frimley Lodge Park, a popular green space offering leisure facilities. Frimley has a vibrant community spirit, reflected in its various local events and clubs. The town’s railway station, dating back to the 19th century, connects it to London and other major cities, highlighting its strategic importance. Frimley’s blend of historical charm and modern amenities makes it a unique place within the UK.

  • CT-EU-00054212

    Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    • aflibercept
    • OPT-302
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Long-term safety study of sebetralstat in treating hereditary angioedema

    This trial is about a medicine sebetralstat also known as KVD900, which is being tested as a treatment to quickly stop swelling attacks in teenagers and adults who have a condition called hereditary angioedema (HAE). HAE is a rare, inherited disorder that causes episodes of swelling in different parts of the body. The study aims to find out how safe this medicine is if used for a long time. People who are 12 years and older and who have HAE type I or II can participate in this trial. One of the things the researchers will look at is how fast symptoms start to get better after taking this new medication.

    • Sebetralstat/KVD900
  • Testing the effect of sebetralstat treatment in hereditary angioedema

    This study focuses on adolescents with hereditary angioedema (HAE) type I or II. It aims to evaluate the effectiveness of Sebetralstat (KVD900), a drug intended to treat this disease. Teenagers taking part in this study will be given KVD900 to see how it affects their symptoms. The study is needed to understand how this drug may help treat HAE in younger patients, offering a potential new treatment option. Throughout the study, participants’ health and response to the drug will be closely monitored, with their safety and well-being being a priority. This research could significantly improve the treatment of hereditary angioedema in adolescents.

    • Sebetralstat/KVD900
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.